seed
Stage
2
Investors
About
ExcepGen develops RNA-based medicines, including self-amplifying and trans-amplifying mRNA vaccines, that improve tolerability by modulating the innate immune response through their RNAx platform technology.
Explore ExcepGen's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.